FDA investigating possible increased risk of death with lymphoma medicine Ukoniq (umbralisib)

F

FDA

Guest
FDA is investigating a possible increased risk of death with the cancer medicine Ukoniq (umbralisib), which is approved to treat two specific types of lymphomas. Patients and health care professionals should discuss the risks and benefits of Ukoniq.


Baca selengkapnya di : http://www.fda.gov...
 
You must log in or register to reply here.
Top